Showing posts with label Biotech. Show all posts
Showing posts with label Biotech. Show all posts

January 10, 2016

BioTech Firms Enthusiastic About Gene Editing Potential To Cure Disease




This announcement is exciting and inspiring. Without guidelines, what prevents use of gene editing on persons, diagnosed as having a disease, which may change brain functions? Psychiatry has a benevolent image, which allows corrupt doctors working for politicians or businessmen to designate a law abiding person insane and taking his freedom, forcing drugs on him. What barrier is there to prevent abuses using gene editing? Has technology outrun human understanding and morality? It is now two or three generations ahead of the law, which is useless controlling technological abuses available now to criminals and corrupt officials. The evolved politicians remain focused on getting re-elected and not offending anyone. 


Editing the brain

[From article]
The research being done at the Stanford School of Medicine, led by Dr. Matthew Porteus, is part of an accelerating research movement made possible using the new technique to try to cure genetic diseases such as sickle cell anemia and muscular dystrophy. These labs are steadily advancing through cell-based and animal trials, as fledgling biotech companies raise large sums of money needed to bring the therapies to market.
"Now, with lots of people -- hundreds or thousands of labs -- working with CRISPR, this means the possibility of actually finding a way to cure patients of disease increases dramatically," said Porteus, an associate professor of pediatrics and a pioneer in gene editing.
Using the campus's first-ever cell manufacturing plant, to be completed this spring, the Stanford team aims to start human trials in 2018. The researchers are targeting two severe blood diseases -- sickle cell anemia and beta thalassemia -- and several diseases that ravage the immune system.
[. . .]



CRISPR has been in the crosshairs of controversy because of its profound potential to rearrange the basic building blocks of life. In December, experts gathered in Washington, D.C., to urge limits to its use in creating dangerous new organisms or "designer babies."
[. . .]
CRISPR -- which stands for "clustered regularly interspaced short palindromic repeats," or clusters of brief DNA sequences that read similarly forward and backward -- is the game changer. Only 3 years old, it works like the search-and-replace function of a computer.
A Palo Alto native who was educated at Harvard and Stanford, Porteus, 51, has spent his lifetime watching helplessly as patients declined from blood and immune system diseases such as sickle cell anemia, beta thalassemia and severe combined immunodeficiency disease.
These are very different diseases, he said. But they have this in common: All are caused by a single mutation in a single gene of a single cell type.
More than 10,000 human diseases are caused by a single gene defect, according to Dr. Maria Grazia Roncarolo, co-director of Stanford's Institute for Stem Cell Biology and Regenerative Medicine.
[. . .]


Snoop, snoop.

In November, the Cambridge, Mass., biotech startup Editas Medicine, co-founded by the Massachusetts Institute of Technology's Dr. Feng Zhang, announced that it planned to test a CRISPR-based gene therapy technique in hopes of curing a rare form of blindness by fixing a gene that controls the eye's photoreceptor cells. It has raised $120 million from investors, including Bill Gates and Google Ventures, on top of $43 million raised in 2013.
In December, the biotech firm CRISPR Therapeutics of Cambridge received an eye-popping $335 million investment from German pharmaceutical giant Bayer AG to form a joint venture that will research CRISPR-based treatments.
More sobering are the challenges posed by many of the world's more common diseases, such as autism, diabetes, heart disease or cancer, which involve multiple genes. And diseases that involve hard-to-reach tissues, such as Alzheimer's, are also daunting.

https://www.arcamax.com/currentnews/newsheadlines/s-1783024

JANUARY 10, 2016 12:00 AM
Researchers bring gene editing to patients with deadly diseases
BY LISA M. KRIEGER
San Jose Mercury News

July 5, 2015

Cambridge City Council Considers 1,000 foot Tall Building




Will a 1,000 foot tall building and 1,000 more housing units improve the quality of life in Cambridge? More people, higher buildings, before you know it Cambridge will be Manhattan north, with the same problems they have there. How exciting it will be. Don't forget 24 hour public transit and retail stores.

http://cambridge.wickedlocal.com/article/20150630/NEWS/150639795

All eyes on Volpe: Huge plans leave Cambridge councilors feeling rushed
By Sara Feijo
sfeijo (at) wickedlocal.com
Posted Jun. 30, 2015 at 3:49 PM
CAMBRIDGE Chronicle

June 29, 2010

Love and Sex by Chemcals and Electricity

Eagan sounds perplexed making no distinction between love and sex. Merging them is a noble goal. Is love not possible without sex? Ask St. Augustine. Can women (or men? Hahaha!) enjoy sex without love? Chemicals marketed by drug companies are for sex, not love. Experimental procedures include using electrical devices to influence human thoughts and emotions. Can technology create love in humans? Can technicians generate sexual attraction without chemicals? Is the Pope German?

http://bostonherald.com/news/columnists/view.bg?articleid=1264547

Sexless and satisfied? Not buying it

By Margery Eagan
Boston Herald
Tuesday, June 29, 2010

November 23, 2009

Biotech Lobbyists for Higher Drug Costs

Biotech Lobbyists for Higher Drug Costs


This essay describes one example of how health care costs are kept artificially high due to lobbyists controlling the public discourse. The same pattern applies to psychiatric drugs.

http://www.prwatch.org/node/8690

Genentech's Ghostwriting Animates Congressional Speeches on Health Reform
Submitted by Lisa Graves
Center for Media & Democracy
November 15, 2009 - 8:26am.

February 2, 2009

Can't You See What that Policy's Been Doing to Me?

Can't You See What that Policy's Been Doing to Me?

[This letter was published in the February 12, 2009 online edition of the Cambridge Chronicle.]

GOP Chair Jennifer Nassour referred to "an appearance of impropriety." (State House News Service, "GOP questions life sciences center meeting in Cambridge," Cambridge Chronicle, February 2, 2009, online edition) A what? Not in this state, Chump. No such thing. Never. Ningun. Nada. All is on the up and up here. With the Conformist Party running the state, how can there possibly be an appearance of anything? All is well here, Pal. Nothing improper at all. It's all in you mind. We are told, "the governor and his administration feel that no one cares and no one's watching and they can get away with this." It is not just the Governor who feels that way. All the politicians know that no one cares. If they do care they get some love from the character assassination squad where they live. No sleep for a few years will teach them to recognize the propriety of all government actions. "The center's spokesman, Angus McQuilken [described] a transparent conflict of interest policy is strictly adhered to by all of our Board members." ALL Board Members, do you hear me? Transparent policy, can't you see? As long as you can see the conflict of interest there is no problem. It is transparent. So what are you complaining about, Buddy?

http://www.wickedlocal.com/cambridge/news/business/x309573577/GOP-questions-life-sciences-center-meeting-in-Cambridge

GOP questions life sciences center meeting in Cambridge
By State House News Service
Cambridge Chronicle
Mon Feb 02, 2009, 06:50 PM EST

Roy Bercaw, Editor ENOUGH ROOM

November 6, 2008

More Taxpayer Funds for Corporate Welfare

More Taxpayer Funds for Corporate Welfare

Maybe Cadillac Deval can find more taxpayer funds to help out the troubled Biotech firms. Is $1 billion enough? If Bush can give the financial firms $850 billion, Deval can give the Biotech firms $5 or $6 billion. It is only fair. Cities can lay off firefighters and police and close libraries to pay for the Biotech funding.

Roy Bercaw, Editor ENOUGH ROOM

http://www.wickedlocal.com/cambridge/news/opinions/x199485800/Letter-Cambridge-needs-to-diversify

Letter: Cambridge needs to diversify
Wed Nov 05, 2008, 04:16 AM EST
Cambridge Chronicle -
PETER SCHWEICH
Brattle Street

October 22, 2008

Enjoying Noise is a Small Sacrifice

Enjoying Noise is a Small Sacrifice

The noise ordinance was not meant for deep pocketed Biotech firms. It was meant to keep the inebriated workers quiet as they leave the adult beverage cafes late at night. It is shocking to think that a city could impose its small-minded ordinances on a research corporation. Are these whiners Luddites or what? Noise is a small price to pay for advancing science. If researchers can kill individuals to benefit society what's wrong with blowing out a few ear drums or missing few hours of sleep? People who harass me, disturb my sleep every hour because they are paid to do so. Your sleep is disturbed to advance science. Sacrifice for your fellow man. As the Hero of the Kennedy cult said, "Ask not what your city can do for you. Ask what you can do for your city and for science?" Why so selfish?

Roy Bercaw, Editor ENOUGH ROOM

http://www.wickedlocal.com/cambridge/news/opinions/x1261534136/Editorial-How-loud-is-too-loud

Editorial: How loud is too loud?
Cambridge Chronicle
Wed Oct 22, 2008, 02:12 PM EDT

Laws are for the Little People

Laws are for the Little People

MA taxpayers gave $1 billion to the Biotech industry so that they would not abandon Massachusetts. Now some disgruntled citizens want to enforce noise ordinances? Is that silly or what? They might leave the state if laws are enforced. Why not an exemption from noise ordinances, and all other laws? Why not treat Idenix as if it were a City agency. Cambridge government violates laws whenever the laws are inconvenient. Why not extend the same privileges to Idenix? Oh and it might help if the citizens who complained were arrested and sent for a competency evaluation. That would stop their annoying complaints.

Roy Bercaw, Editor ENOUGH ROOM

http://www.wickedlocal.com/cambridge/news/x1348680924/Neighbors-make-some-noise-over-noise-Company-seeks-variance-to-keep-rooftop-machinery-going

Neighbors make some noise over noise: Company seeks variance to keep rooftop machinery going
By Jillian Fennimore/
Cambridge Chronicle staff
Tue Oct 21, 2008, 01:16 PM EDT

November 2, 2007

Deval and the Biotech Devils

Deval and the Biotech Devils

Deval Patrick lost touch with reality. His moonbat base may believe his
allegation that his $1 billion boondoggle is "critical for Massachusetts to help
biotech, pharmaceutical and other life-sciences companies - or firms will be
lured away."(Jay Fitzgerald and Scott Van Voorhis, "Gov: Bio-bill delay costly,"
Boston Herald, October 31, 2007) Novartis, Biogen etc., landed in Cambridge
because of access to academic researchers at MIT and Harvard. They are not going
anywhere.
Stealing more money from the poor taxpayer to give to the wealthy biotech
industry is not necessary. Deval sounds more and more each day like the Harvard
corporate lawyer that he is.

Roy Bercaw, Editor ENOUGH ROOM

Gov: Bio-bill delay costly
Slams pol on Novartis loss
By Jay Fitzgerald and Scott Van Voorhis
Boston Herald
Wednesday, October 31, 2007 |

Gov. Deval Patrick yesterday blamed the Legislature’s lack of action on his $1
billion life-sciences bill for Novartis AG’s decision to build a new biotech
facility in Singapore, not Massachusetts.

Patrick, who has been critical of the slow pace of legislative action on a
number of his proposals, told lawmakers at a State House hearing yesterday that
it’s critical for Massachusetts to help biotech, pharmaceutical and other
life-sciences companies - or firms will be lured away.

He said some biotech companies have decided to expand operations here, partly
because of state economic incentives offered to them.

“But not everyone is convinced that we mean it,” he told the Joint Committee on
Economic Development and Emerging Technologies.

“One large company - Novartis - was prepared to invest hundreds of millions of
dollars in over 700,000 square feet of lab and office space creating over 400
new, well-paying jobs. But our inaction on this proposal over many months caused
them to abandon those plans here and focus instead on other states.”

Patrick was referring to Novartis’ decision to build a new major plant in
Singapore, after looking at sites in Massachusetts.

After the hearing, Patrick declined to give details about what Novartis wanted.
But he reiterated that the Legislature’s failure to quickly pass his bill had an
impact.

“Inaction sends a message,” said Patrick.

In the past, lawmakers have bristled at Patrick’s criticism of the slow pace of
work at the State House, suggesting the first-year governor doesn’t understand
the legislative process. A handful of key lawmakers have also questioned whether
the biotech industry should get so much extra money from the state.

Jeff Lockwood, a spokesman for Novartis, declined to comment on whether the slow
legislative progress was behind the company’s decision to expand in Singapore.
He said the move was based on a “multitude of factors.”
Article URL:
http://www.bostonherald.com/business/general/view.bg?articleid=1041566

September 2, 2007

Trusting Politicians and the Biotech Industry

Trusting Politicians and the Biotech Industry

Can a responsible journalist question the ethics of a lawyer, a politician
or a biotech corporation? (Joan Vennochi, "Troubling beginnings for biotech
council chief," Boston Globe, August 30, 2007, page A9) This is the biotech
industry. They bring more food to poor people. They cure illnesses. They can do
no wrong. And even if they do wrong the benefit to society outweighs any harm to
individuals. That was the defense of the Nazi doctors at Nuremberg.
This is another administration led by a Harvard lawyer. Is there a question
about the integrity of Harvard corporate lawyers too? The biotech industry wants
taxpayer funding for research. They will share those funds with the politicians.
They are not greedy.
Vennochi discusses the connections of politics to human services
corporations, which are not for profit. Ahem! Are there abuses in the industry
which employs the caring professions? Are they suspected of wrongdoing? I am
shocked.

Roy Bercaw, Editor, ENOUGH ROOM

Troubling beginnings for biotech council chief
Boston Globe
By Joan Vennochi
August 30, 2007

FOR THE MASSACHUSETTS Biotechnology Council, the desire for political access is
also a prescription for political controversy.

The council's new president, Robert K. Coughlin, is already defending himself
against charges that he violated the state conflict-of-interest law. Coughlin
just replaced former speaker of the House Thomas M. Finneran, who was forced to
quit as president after pleading guilty to a felony obstruction-of-justice
charge.

Whoosh! Talk about a revolving door. In about six months, Coughlin went from a
job as one of the governor's top liaisons to the biotech industry to talking
about a job as that industry's top advocate. Then, it took Coughlin six weeks to
disclose those discussions to the state. At the same time, he was working on
major state biotech initiatives.

A former state legislator, Coughlin is well connected. He is related to Jack
Connors Jr., chairman of Partners Healthcare, the powerful umbrella organization
for Harvard teaching hospitals. Connors served as an employment reference for
Coughlin, who is his second cousin; so did Joe O'Donnell, a prominent Boston
businessman who runs The Joey Fund, a charity named after his son, who died of
cystic fibrosis. Coughlin, who also raises money for the charity, has a
5-year-old son who has the disease. That could make him a compelling advocate
for the industry.

But whether he followed the law still matters.

Coughlin first met with members of the biotech council's search committee on
June 11. He had a second meeting on June 13. But not until July 19 did he inform
his immediate boss, Secretary of Housing and Economic Affairs Daniel O'Connell,
of his discussions. On July 20, he notified Governor Deval Patrick, according to
Cyndi Roy, a spokeswoman for the governor. On July 24, he filed a formal
disclosure with the state ethics commission. He was hired Aug. 13.

The state's conflict-of-interest law requires disclosure when a state employee
participates in a matter "in which he . . . or any organization with whom he is
negotiating . . . concerning prospective employment has a financial interest."

Coughlin's lawyer, Thomas R. Kiley, told the Globe's Frank Phillips that the
June 11 meeting wasn't an interview or negotiation; it was a "meet and greet."
Kiley told me that once Coughlin became a job candidate, no matter was discussed
"in which the Massachusetts biotech council has any financial interests." Asked
about Coughlin's financial interest in landing a job that could pay up to
$500,000, Kiley said, "That's not what the statute is about." He then declared
himself too busy for further conversation and ended the telephone call.
[...]
Joan Vennochi's e-mail address is vennochi@globe.com.

Trust Us, We're Biotech!

Trust Us, We're Biotech!

Trust us we're biotech companies! How can the Cambridge Chronicle question
the methods and procedures of a biotech company? Are any reporters experts? Huh?
(Editorial, "We deserve to know GateHouse News Service, Aug 30, 2007) Biotech
companies improve the health and welfare of all persons. Biotech companies make
more food and more varieties available to poor people. Biotech companies cure
illnesses. Biotech companies employ only high-minded ethical researchers who
only do good. Biotech companies never harm humans or rodents.
What is wrong with the people at the Cambridge Chronicle questioning how a
concerned compassionate company stores its chemicals? There are no dangers, only
benefits from the way we store our chemicals. We support diversity, and equal
rights.
We are biotech companies and we want your money. Support Harvard's
Corporate lawyer and Governor, Deval "Cadillac" Patrick's $1 billion promise or
we will leave Cambridge. We want your money. We are biotech companies. If you
can't trust us who can you trust? We'll share your money with the politicians.
We're not greedy.

[See e.g.,

Drug co.: Pass biotech $$ plan or else
By Scott Van Voorhis
Boston Herald Business Reporter
Friday, August 31, 2007 - Updated: 03:30 AM EST

British pharmaceutical giant Shire PLC yesterday warned that plans for a major
drug manufacturing complex in Boston’s suburbs could be in jeopardy unless
Beacon Hill passes a trumpeted, $1 billion incentive package for the life
sciences industry.
...]

Roy Bercaw, Editor, ENOUGH ROOM

Editorial: We deserve to know
GateHouse News Service
Thu Aug 30, 2007, 06:08 AM EDT
Cambridge -
What’s really going on at Idenix Pharmaceuticals?

We couldn’t tell you because we don’t know. The company won’t tell neighbors,
either. Idenix, which develops drugs for viral and infectious diseases, wants to
increase its storage capacity of unknown solvents from 165 gallons to 2,000
gallons in its Hampshire Street facility. It’s a heck of an increase for any
chemical. The company says it isn’t required to make the information public; at
the same time, it’s seeking a license from the city to store 12 times the volume
of solvents it currently has. The reason? Homeland Security.

While we realize such sensitive information might be a risk to the public
safety, we think the risks of withholding that information would be even more
damaging. One unconfirmed chemical that neighbors have been tossing around as
one that could be in storage is dichloromethane, a known carcinogen commonly
used in pharmaceutical manufacturing. The company would neither confirm or deny
its existence at the site.
[...]